Fig. 4
From: Matrix-M™ adjuvation broadens protection induced by seasonal trivalent virosomal influenza vaccine
Matrix-M™ adjuvated TVV enhances protection against heterologous H1N1 H3N2 and influenza B strains. Mice (n = 10/group) were immunized once with TVV (containing 3μg HA per strain) with or without Matrix-M™. Four weeks later, mice were challenged with 25xLD50 of mouse-adapted heterologous H1N1 A/Brisbane/59/07, H3N2 A/Hong Kong/01/68 or B/Florida/04/06 and monitored for 21 days for survival, body weight loss (clinical symptoms, Additional file 3: Figure S2A). Graphs represent the Kaplan-Meier survival curves (left) and mean body weight change with 95 % confidence interval (right). Asterisks indicate statistically significant differences from the vehicle control group (*p < 0.05, ** p < 0.01, ***p < 0.001, according to the materials and methods section)